Funding Daily Summary
Funding Daily Summary: What Happened on October 27, 2026
Atlas Bio launches with $12.5 million for drug-response simulations
The company says its AI platform uses human-tissue data to model how patients may respond to treatments.
Today in brief
Atlas Bio emerged from stealth with $12.5 million to develop AI-based drug-response simulations.1
Funding and platform
Atlas Bio disclosed a $10 million seed round led by Creandum and a $2.5 million pre-seed round led by First Momentum Ventures and LEA Partners.1 The company says it will use the funding for scientific and commercial hiring, platform validation and gaining more enterprise customers.1
Atlas Bio says its model learned from about 2 million human-tissue RNA readouts and estimates how patient profiles may respond to treatments.1